IRIS
FERRARA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.782
NA - Nord America 640
EU - Europa 570
SA - Sud America 266
AF - Africa 18
AN - Antartide 1
Totale 4.277
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 1.953
US - Stati Uniti d'America 564
CN - Cina 341
HK - Hong Kong 307
RO - Romania 264
BR - Brasile 229
IT - Italia 95
VN - Vietnam 88
GB - Regno Unito 39
DE - Germania 38
MX - Messico 37
CA - Canada 32
NL - Olanda 22
AR - Argentina 17
PL - Polonia 17
SE - Svezia 17
IN - India 15
TR - Turchia 15
FR - Francia 14
ZA - Sudafrica 13
BD - Bangladesh 12
FI - Finlandia 12
LT - Lituania 12
ES - Italia 11
ID - Indonesia 8
RU - Federazione Russa 8
UA - Ucraina 8
AT - Austria 6
EC - Ecuador 6
JP - Giappone 6
CO - Colombia 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
IQ - Iraq 4
UZ - Uzbekistan 4
JO - Giordania 3
KZ - Kazakistan 3
SA - Arabia Saudita 3
VE - Venezuela 3
IE - Irlanda 2
IL - Israele 2
MA - Marocco 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
TT - Trinidad e Tobago 2
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
OM - Oman 1
PE - Perù 1
PY - Paraguay 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.277
Salva come PNG Salva come JPEG
Città #
Hong Kong 304
Singapore 235
Dallas 127
Beijing 120
Ashburn 105
Hefei 95
New York 41
Ho Chi Minh City 36
Los Angeles 35
Mexico City 22
Milan 22
São Paulo 22
Denver 18
Warsaw 14
Montreal 13
Munich 13
Brooklyn 11
Rome 11
Stockholm 11
Hanoi 10
Ankara 9
Cesano Boscone 9
Manchester 9
Poplar 9
Rio de Janeiro 9
Toronto 9
Boardman 8
Boston 8
Falkenstein 8
Johannesburg 8
Phoenix 8
Shanghai 8
Helsinki 7
Houston 7
Assago 6
Brasília 6
Frankfurt am Main 6
Nuremberg 6
Orem 6
Amsterdam 5
Chennai 5
Florence 5
Kyiv 5
Porto Alegre 5
Querétaro 5
Rotherham 5
Santa Clara 5
Seattle 5
Campinas 4
Da Nang 4
Dhaka 4
Goiânia 4
Haiphong 4
London 4
Milwaukee 4
Shenzhen 4
Tashkent 4
Tokyo 4
Aalsmeer 3
Baie-D'Urfé 3
Bauru 3
Blumenau 3
Calgary 3
Can Tho 3
Fortaleza 3
Guangzhou 3
Guarulhos 3
Istanbul 3
Miami 3
Quilmes 3
Quito 3
Ribeirão Preto 3
Sorocaba 3
Teresópolis 3
Turku 3
Vilnius 3
Americana 2
Amman 2
Atlanta 2
Baghdad 2
Belo Horizonte 2
Biên Hòa 2
Bogotá 2
Buenos Aires 2
Cape Town 2
Caracas 2
Changsha 2
Chicago 2
City of London 2
Cleveland 2
Gravataí 2
Guayaquil 2
Ha Long 2
Hangzhou 2
Helena 2
Honcho 2
Hyderabad 2
Hải Dương 2
Itaboraí 2
Itanhaém 2
Totale 1.598
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 325
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer 168
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 168
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 166
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 163
OncoAlert Round Table Discussions: The Global COVID-19 Experience 160
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) 155
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 149
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 133
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 112
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 78
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 63
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 60
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation 59
Hyperprogressive disease: recognizing a novel pattern to improve patient management 58
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy 55
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 54
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 53
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study 52
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 50
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer 50
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 47
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression 44
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 44
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer 43
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer 43
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study 41
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer 41
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 40
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? 38
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy 38
Immunotherapy 37
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 37
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 37
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 37
A Case of William's Syndrome in a Ugandan Child: A Feasible Diagnosis Even in a Low-Resource Setting 36
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 36
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation 36
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter 35
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 35
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events 35
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 35
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers 34
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 33
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 33
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 32
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort 31
SMO mutations confer poor prognosis in malignant pleural mesothelioma 30
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective 30
Atypical patterns of response and progression in the era of immunotherapy combinations 29
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 28
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 28
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC 28
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 28
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis 28
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 28
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? 27
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 27
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria 26
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy 26
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy 26
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 26
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 26
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 26
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 26
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer 25
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer 25
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors 25
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 25
Do immune checkpoint inhibitors need new studies methodology? 25
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer 24
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 24
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy 24
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply 22
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? 22
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 22
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases 21
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments 21
Unexpected Huge Prevalence of Intracardiac Extension of Wilms Tumor—A Single Center Experience from a Ugandan Hospital 21
The development of PARP as a successful target for cancer therapy 21
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients 21
Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers 20
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients 20
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer 20
Progress in the Management of Advanced Thoracic Malignancies in 2017 19
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 19
Is hyperprogressive disease a specific phenomenom of immunotherapy? 19
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 19
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 18
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 18
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? 17
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply 16
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 14
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer 6
Totale 4.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.260
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.260
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 2 0 0 0 0 0 0 0 0 0
2022/202314 3 2 1 0 0 1 1 2 0 0 2 2
2023/202440 2 4 2 2 2 5 6 3 3 3 1 7
2024/20252.532 16 6 1 6 9 7 404 66 214 300 761 742
2025/20261.807 383 308 146 440 413 117 0 0 0 0 0 0
Totale 4.395